# Black Diamond Therapeutics (BDTX) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/BDTX
## Company Profile
- Ticker: BDTX
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Oncology
## Stock Data
- Close: 2.09 USD
- Market cap: 124917867.32000001 USD
- Last updated: 2026-08-11
## Business Overview
### Mutation-Family Precision Oncology
Black Diamond Therapeutics develops MasterKey therapies designed to inhibit families of oncogenic mutations with a single small molecule.
### Silevertinib
Silevertinib is a brain-penetrant kinase inhibitor targeting canonical and noncanonical EGFR mutations, including alterations that are difficult to address with mutation-specific drugs.
### Frontline Lung Cancer
The Phase 2 non-small cell lung cancer program is evaluating response durability, progression-free survival and dose selection in patients with newly diagnosed EGFR-mutated disease.
### Glioblastoma
A separate Phase 2 study evaluates silevertinib in newly diagnosed EGFRvIII-positive glioblastoma, using the candidate's brain penetration to address a distinct EGFR-driven tumor.
## Why The Stock Is Moving

As of Aug 11, 2026, BDTX closed up 5.56% at $2.09. No new same-company headline was identified in the current news window.

## Future Catalysts

- Phase 2 frontline EGFR-mutated NSCLC data, including preliminary duration-of-response and progression-free-survival results, at ASCO 2026.

## Recent News
- 2026-08-05 20:01 EST — [Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/BDTX/black-diamond-therapeutics-reports-second-quarter-2026-financial-results-and-pro-1f4c0ee2) — Source: Black Diamond Therapeutics
- 2026-05-22 12:00 EST — [Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/BDTX/black-diamond-therapeutics-to-participate-in-jefferies-global-healthcare-confere-9abd2552) — Source: Black Diamond Therapeutics
- 2026-05-21 21:14 EST — [Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations](https://biopharmsignal.com/news/BDTX/black-diamond-therapeutics-announces-positive-phase-2-results-for-silevertinib-in-frontline-nsclc-patients-with-egfr-non-classical-mutations) — Source: Black Diamond Therapeutics
- 2026-05-19 12:00 EST — [Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC](https://biopharmsignal.com/news/BDTX/black-diamond-therapeutics-to-host-webcast-for-investors-highlighting-updated-results-from-phase-2-trial-of-silevertinib-in-1l-egfrm-nsclc) — Source: Black Diamond Therapeutics
- 2026-05-07 11:30 EST — [Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/BDTX/black-diamond-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-update) — Source: Black Diamond Therapeutics